Literature DB >> 7642473

Bcl-2: prevention of apoptosis as a mechanism of drug resistance.

J C Reed1.   

Abstract

Programmed cell death (also known as apoptosis) plays an essential role in tissue homeostasis, where it ensures that new cell production in the body is offset by a commensurate rate of cell loss. Defects in the genetic pathway that regulate the cell death process can figure prominently in the origins of cancer and also in problems with cancer treatment. Eventually, it may be possible to develop novel treatments for cancer that specifically seek to modulate the physiologic cell death pathway as opposed to nearly all currently available drugs, which are intended to interfere with some aspect of the cell division cycle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642473

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  40 in total

Review 1.  Mitochondria in Ca2+ signaling and apoptosis.

Authors:  S S Smaili; Y T Hsu; R J Youle; J T Russell
Journal:  J Bioenerg Biomembr       Date:  2000-02       Impact factor: 2.945

Review 2.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

3.  Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1.

Authors:  H G Wang; S Takayama; U R Rapp; J C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival.

Authors:  P Stattin; J E Damber; L Karlberg; H Nordgren; A Bergh
Journal:  Urol Res       Date:  1996

5.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Authors:  Leena Gandhi; D Ross Camidge; Moacyr Ribeiro de Oliveira; Philip Bonomi; David Gandara; Divis Khaira; Christine L Hann; Evelyn M McKeegan; Elizabeth Litvinovich; Philip M Hemken; Caroline Dive; Sari H Enschede; Cathy Nolan; Yi-Lin Chiu; Todd Busman; Hao Xiong; Andrew P Krivoshik; Rod Humerickhouse; Geoffrey I Shapiro; Charles M Rudin
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

6.  The role of oncogenes in drug resistance.

Authors:  D Yu
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

7.  Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival.

Authors:  S Gollapud; S Gupta
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

8.  Programmed cell death (apoptosis) in cord blood lymphocytes.

Authors:  S Aggarwal; A Gupta; S Nagata; S Gupta
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

9.  Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.

Authors:  M Gorospe; J M Egan; B Zbar; M Lerman; L Geil; I Kuzmin; N J Holbrook
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

10.  A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.

Authors:  Glenn Liu; Jill Kolesar; Douglas G McNeel; Catherine Leith; Kathy Schell; Jens Eickhoff; Fred Lee; Anne Traynor; Rebecca Marnocha; Dona Alberti; James Zwiebel; George Wilding
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.